2Suto MJ Stier MA Werbe1 LM et a1.A new c1ass of ana1ogues of the bifunctiona1 radiosensitizer a- ( 1-aziridiny1methy1 ) -2-nitro-1H-imidazo1e-1-ethano1 ( RSU 1069 ) : the cyc1oa1ky1aziridines[J1[J].J Med Chem,1991,34(8):2484-2488.
5Siemann DW. 10th international conference on chemical modifiers on cancer treatment[ C ]. Florida : USA, 1998.56 -102.
6Adams GE. 8th international conference on chemical modifiers oncancer treatment[ C]. Kyoto: Pergamon, 1993.10 - 1.
7Murayama C, Mori T. Radiosensitization by hypoxic cell radiosensltizer-present status of radiosensitizer [ J]. Gan No Rinsho, 1990,36(13) : 2249 - 2254.
8Beard C, 13uswell L, Rose MA. Phase Ⅱ trial of external beam radiation with etanidazole (SR-2508) for the treatment of locally advanced prostate cancer [ J]. Int J Radiat Oncol Biol Phys,1994,29(3):611- 616.
9Sasai K, Shibamoto Y, Takahashi M, et al. K1H-802, an acetohydroxamic acid derivative of 2-nitroimidazole,as a new potent hypoxic cell radio~ensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics[ J ]. Cancer Chemother Pharmacol, 199026(2):112- 116.
10Hideko N, Masahiro B, Bando B, et al. Radiosensitizing, toxicological,and pharmacokinetic properties of hydroxamate analogues of nitroimidazoles as bifunetional radiosensitizers/chemical modifiers[J]. Int J Radiation Oncology Biol Phys, 1992,22 ( 3 ) :561 - 564.
